14:39:06 Europe / Stockholm

Prenumeration

2024-07-15 08:34:00

Redeye reduces its Base Case slightly despite cutting its 2024-2025 EBIT forecasts following a mixed Q2 report. While the issues in Public Deliveries persisted, hurting sales and EBIT in the quarter, the most important metric, the ACV, had an encouraging rebound to solid levels. In summary, it is a soft quarter with robust forward-looking numbers – which is the most important.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/